Background: Mirtazapine (MRZ) is a human antidepressant drug metabolized to 8-OH mirtazapine (8-OH) and dimethylmirtazapine (DMR) metabolites. Recently, this drug has been proposed as a potential analgesic for use in a multidrug analgesic regime in the context of veterinary medicine. The aim of this study was to assess the pharmacokinetics of MRZ and its metabolites DMR and 8-OH in rats. Findings: Eighteen fasted, healthy male rats were randomly divided into 3 groups (n=6). Animals in these groups were respectively administered MRZ at 2 and 10 mg/kg orally and 2 mg/kg intravenously. Plasma MRZ and metabolite concentrations were evaluated by HPLC-FL detection method. After intravenous administration, MRZ was detected in all subjects, while DMR was only detected in three. 8-OH was not detected. After oral administration, MRZ was detected in 3 out of 6 rats treated with 2 mg/kg, it was detected in 6 out of 6 animals in the 10 mg/kg group. DMR was only detectable in the latter group, while 8-OH was not detected in either group. The oral bioavailability was about 7% in both groups. Conclusions: The plasma concentration of the MRZ metabolite 8-OH was undetectable, and the oral bioavailability of the parental drug was very low.
|Autori:||Rouini M.R.; Lavasani H.; Sheikholeslami B.; Owen H.; Giorgi M.|
|Titolo:||PHARMACOKINETICS OF MIRTAZAPINE AND ITS MAIN METABOLITES AFTER SINGLE INTRAVENOUS AND ORAL ADMINISTRATIONS IN RATS AT TWO DOSE RATES|
|Anno del prodotto:||2014|
|Digital Object Identifier (DOI):||10.1186/2008-2231-22-13|
|Appare nelle tipologie:||1.1 Articolo in rivista|